Skip to main navigation Skip to search Skip to main content

Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome

  • Paari Murugan
  • , Liwei Jia
  • , Renzo G. Dinatale
  • , Melissa Assel
  • , Nicole Benfante
  • , Hikmat A. Al-Ahmadie
  • , Samson W. Fine
  • , Anuradha Gopalan
  • , Judy Sarungbam
  • , S. Joseph Sirintrapun
  • , A. Ari Hakimi
  • , Paul Russo
  • , Ying Bei Chen
  • , Satish K. Tickoo
  • , Victor E. Reuter

Research output: Contribution to journalArticlepeer-review

Abstract

The morphologic spectrum of type 1 papillary renal cell carcinoma (PRCC) is not well-defined, since a significant proportion of cases have mixed type 1 and 2 histology. We analyzed 199 cases of PRCC with any (even if focal) type 1 features, with a median follow-up of 12 years, to identify clinicopathological features associated with outcome. Ninety-five tumors (48%) of the cohort contained some type 2 component (median amount: 25%; IQR: 10%, 70%). As a group they showed high rates of progression-free (PFS) and cancer-specific survival (CSS). Tumor size, mitotic rate, lymphovascular invasion, sarcomatoid differentiation, sheet-like architecture, and lack of tumor circumscription were significantly associated with CSS (p ≤ 0.015) on univariate analysis. While predominant WHO/ISUP nucleolar grade was associated with PFS (p = 0.013) and CSS (p = 0.030), the presence of non-predominant (<50%) nucleolar grade did not show association with outcome (p = 0.7). PFS and CSS showed no significant association with the presence or the amount of type 2 morphology. We compared the molecular alterations in paired type 1 and type 2 areas in a subset of 22 cases with mixed type 1 and 2 features and identified 12 recurrently mutated genes including TERT, ARID1A, KDM6A, KMT2D, NFE2L2, MET, APC, and TP53. Among 78 detected somatic mutations, 61 (78%) were shared between the paired type 1 and type 2 areas. Copy number alterations, including chromosome 7 and 17 gains, were similar between type 1 and 2 areas. These findings support that type 2 features in a PRCC with mixed histology represent either morphologic variance or clonal evolution. Our study underscores the notion that PRCC with any classic type 1 regions is best considered as type 1 PRCC and assigned the appropriate WHO/ISUP nucleolar grade. It provides additional evidence that type 2 PRCC as a separate category should be re-assessed and likely needs to be abandoned.

Original languageEnglish (US)
Pages (from-to)825-835
Number of pages11
JournalModern Pathology
Volume35
Issue number6
DOIs
StatePublished - Jun 2022

Bibliographical note

Funding Information:
We gratefully acknowledge the members of the Molecular Diagnostics Service in the Department of Pathology, the Integrated Genomics Operation and Bioinformatics Core, and the Marie-Josée and Henry R. Kravis Center for Molecular Oncology of MSKCC. The study is supported by Memorial Sloan Kettering Cancer Center Core Grant (P30 CA008748).

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome'. Together they form a unique fingerprint.

Cite this